Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Acorda Therapeutics Got Crushed Today

By Maxx Chatsko - Nov 15, 2017 at 2:07PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company provided an update on one of its lead drug candidates.

What happened

Shares of biopharma Acorda Therapeutics (ACOR -12.14%) dropped as much as 40.1% Wednesday after the company issued an update on its second-leading drug candidate. The company is increasing the frequency it evaluates white blood cell count in patients participating in a phase 3 program (which includes three studies) evaluating tozadenant as a potential treatment for Parkinson's disease. The extra monitoring is being conducted after doctors discovered an increased rate of agranulocytosis, a severe reduction in white blood cell count, which is "possibly drug-related" and is sometimes associated with sepsis and death. White blood cells play a critical role in the body's immune system by fighting off infection.

Acorda Therapeutics noted that to date, approximately 890 patients have been treated with tozadenant and 234 with a placebo. Seven cases of sepsis have occurred, all in tozadenant groups, and four cases were fatal and related to agranulocytosis. The company is currently in discussions with the U.S. Food and Drug Administration and the independent Data Safety Monitoring Board.

As of 12:42 p.m. EST, the stock had settled to a 37.6% loss.

A businessman holding out his hand with a bar chart showing losses hovering over it.

Image source: Getty Images.

So what

Patient safety concerns are never good for a drug candidate or marketed treatment. News such as this can affect potential marketing approval decisions and/or significantly reduce a treatment's approved indications or market potential. Investors aren't taking any chances.

That's because Acorda Therapeutics' lead product, Ampyra, is expected to lose marketing exclusivity in July 2018. The product is expected to generate $535 million to $545 million in revenue this year, which will amount to substantially all of the company's total revenue for 2017. 

To counter the expected threat to revenue in the second half of 2018, the company executed a significant corporate restructuring to focus resources on its late-stage drug pipeline. That includes CVT-301, an inhaled product for treating Parkinson's disease that successfully completed multiple phase 3 studies, and tozadenant. Things haven't been going smoothly.

Acorda Therapeutics submitted a New Drug Application (NDA) to the FDA earlier this year, but the FDA responded with a Refusal To File (RTF) letter stating the NDA contained insufficient information for the agency to complete a review. The pair are in discussions to resolve the issues raised in the RTF. Of course, Wednesday's news means the company's top-two drug candidates are stumbling at a critical time.

Now what

It's very important for the company to begin diversifying revenue with new products, which explains why investors are skittish over recent events affecting the leading drug candidates. Unfortunately, there's not much investors can do at this point except remain patient or move on from Acorda Therapeutics stock altogether. The uncertainty surrounding how things will play out definitely increases the risk involved with an investment.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Acorda Therapeutics, Inc. Stock Quote
Acorda Therapeutics, Inc.
$0.58 (-12.14%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.